Looks like there`s been an error while trying to load this page.
Our team has been notified but please contact us using the email support widget if the problem persists.
Metrics | Range | Conclusion |
---|---|---|
Selected LTM Ps Multiple | 4.7x - 5.2x | 4.9x |
Selected Fwd Ps Multiple | 3.7x - 4.1x | 3.9x |
Fair Value | $19.79 - $21.87 | $20.83 |
Upside | -7.8% - 1.9% | -2.9% |
Benchmarks | Ticker | Full Ticker |
---|---|---|
Dyadic International, Inc. | - | NasdaqCM:DYAI |
Cardiff Oncology, Inc. | - | NasdaqCM:CRDF |
Geron Corporation | - | NasdaqGS:GERN |
Trevena, Inc. | - | OTCPK:TRVN |
Ainos, Inc. | - | NasdaqCM:AIMD |
Catalyst Pharmaceuticals, Inc. | - | NasdaqCM:CPRX |
Select Price / LTM Sales Ratio | ||||||||
Benchmark Companies | ||||||||
DYAI | CRDF | GERN | TRVN | AIMD | CPRX | |||
NasdaqCM:DYAI | NasdaqCM:CRDF | NasdaqGS:GERN | OTCPK:TRVN | NasdaqCM:AIMD | NasdaqCM:CPRX | |||
Historical Sales Growth | ||||||||
5Y CAGR | 15.8% | 22.8% | 178.4% | -11.4% | 12.1% | 36.9% | ||
3Y CAGR | 13.3% | 23.9% | 280.9% | 0.6% | -67.3% | 51.7% | ||
Latest Twelve Months | 57.6% | -3.8% | 22264.0% | -83.0% | 13.4% | 30.0% | ||
Historical Net Income Profit Margin | ||||||||
5 Year Average Margin | -386.3% | -7679.2% | -23165.6% | -19680.3% | -12542.7% | 35.8% | ||
Prior Fiscal Year | -234.4% | -8496.9% | -77690.7% | 12839.7% | -11277.0% | 17.9% | ||
Latest Fiscal Year | -166.2% | -6655.2% | -226.7% | -1289.2% | -71702.3% | 33.3% | ||
Latest Twelve Months | -163.9% | -8326.7% | -119.5% | -6233.7% | -13967.4% | 36.9% | ||
Current Trading Multiples | ||||||||
EV / LTM EBITDA | NA | -3.2x | -4.3x | -0.8x | -2.5x | 7.5x | ||
Price / LTM Sales | 8.0x | 414.8x | 7.8x | 1.7x | 128.7x | 4.9x | ||
LTM P/E Ratio | -4.9x | -5.0x | -6.6x | 0.0x | -0.9x | 13.3x | ||
Low | Mid | High | ||||||
Benchmark LTM P/S Ratio | 1.7x | 8.0x | 414.8x | |||||
Historical LTM P/S Ratio | 2.9x | 5.2x | 10.1x | |||||
Selected Price / Sales Multiple | 4.7x | 4.9x | 5.2x | |||||
(x) LTM Sales | 535 | 535 | 535 | |||||
(=) Equity Value | 2,501 | 2,632 | 2,764 | |||||
(/) Shares Outstanding | 122.0 | 122.0 | 122.0 | |||||
Implied Value Range | 20.50 | 21.58 | 22.66 | |||||
FX Rate: USD/USD | 1.0 | 1.0 | 1.0 | Market Price | ||||
Implied Value Range (Trading Cur) | 20.50 | 21.58 | 22.66 | 21.46 | ||||
Upside / (Downside) | -4.5% | 0.6% | 5.6% |
Equity Value | |||||||
Benchmark Companies | |||||||
(in millions) | DYAI | CRDF | GERN | TRVN | AIMD | CPRX | |
Value of Common Equity | 28 | 243 | 911 | 1 | 14 | 2,618 | |
(/) Shares Outstanding | 30.1 | 66.5 | 636.9 | 1.0 | 4.2 | 122.0 | |
Implied Stock Price | 0.94 | 3.66 | 1.43 | 0.94 | 3.29 | 21.46 | |
FX Conversion Rate to Trading Currency | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | |
Implied Stock Price (Trading Cur) | 0.94 | 3.66 | 1.43 | 0.94 | 3.29 | 21.46 | |
Trading Currency | USD | USD | USD | USD | USD | USD | |
FX Rate to Reporting Currency | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
The video below provides an overview of the key benefits to help you get the most out of InvestingPro.